Skip to main content

Table 6 PROGRESS 10 highest enrolling countries and 10 highest drotrecogin alfa (activated) using countries

From: The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

    DrotAA-treated patients
Country Number of sites Enrolled patients,
n (% overall)
(n = 12,492)
n, (% of total DrotAA patients)
[Overall rank]
(n = 882)
Within-country DrotAA use,
% (DrotAA patients/Total patients) [Rank]
Germany* 17 1810 (14.5) 98 (11.1) [3] 5.4 (98/1810) [11]
Argentina* 18 1269 (10.1) 22 (2.5) [9] 1.7 (22/1269) [15]
Canada* 12 1213 (9.7) 101 (11.5) [2] 8.3 (101/1213) [7]
Brazil* 9 968 (7.7) 65 (7.4) [4] 6.7 (65/968) [9]
India* 21 803 (6.4) 29 (3.3) [8] 3.6 (29/803) [12]
United States* 26 760 (6.1) 206 (23.3) [1] 27.1 (206/760) [2]
Australia* 4 667 (5.3) 53 (6.0) [6] 7.9 (53/667) [8]
Malaysia* 4 641 (5.1) 12 (1.4) [11] 1.9 (12/641) [14]
Philippines* 10 489 (3.9) 10 (1.1) [12] 2.0 (10/489) [13]
Mexico* 10 475 (3.8) 54 (6.1) [5] 11.4 (54/475) [6]
Belgium 7 360 (2.9) 43 (4.9) [7] 11.9 (43/360) [5]
Poland 10 210 (1.7) 29 (3.3) [8] 13.8 (29/210) [4]
New Zealand 1 145 (1.2) 9 (1.0) [13] 6.2 (9/145) [10]
Turkey 16 128 (1.2) 43 (4.9) [7] 33.6 (43/128) [1]
Algeria 6 105 (0.8) 19 (2.2) [10] 18.1 (19/105) [3]
  1. * Top 10 enrolling countries.
  2. Top 10 countries with highest within-country DrotAA use (enrollment >100 patients)
  3. Numbers in brackets, [], relate to a country's rank for DrotAA patients and within country use
  4. DrotAA = drotrecogin alfa (activated); MODS = multiple organ dysfunction syndrome; PROGRESS = Promoting Global Research Excellence in Severe Sepsis.